Maxon Introduces Cinebench 2024
5.9.2023 16:06:00 EEST | Business Wire | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists and creators of all types, is thrilled to announce the highly anticipated release of Cinebench 2024. This latest iteration of the industry-standard benchmarking software, which has been a cornerstone in computer performance evaluation for two decades, sets a new standard for performance evaluation, embracing cutting-edge technology to provide artists, designers, and creators with a more accurate and relevant representation of their hardware capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905630586/en/
Maxon Introduces Cinebench 2024: A New Standard for Performance Evaluation (Photo: Business Wire)
Redshift Rendering Engine Integration
Cinebench 2024 ushers in a new era by embracing the power of Redshift, Cinema 4D's default rendering engine. Unlike its predecessors, which utilized Cinema 4D's standard renderer, Cinebench 2024 utilizes the same render algorithms across both CPU and GPU implementations. This leap to the Redshift engine ensures that performance testing aligns seamlessly with the demands of modern creative workflows, delivering accurate and consistent results.
Dual Performance Evaluation: CPU and GPU
Cinebench 2024 reinstates GPU benchmarking, a feature absent from Cinebench for the past decade. The latest version not only evaluates CPU performance; it also provides insights into the GPU's capabilities, reflecting the evolving technological landscape of creative software and workflows.
Wider Platform Compatibility
Cinebench 2024 is designed to accommodate a broader range of hardware configurations. It seamlessly supports x86/64 architecture (Intel/AMD) on Windows and macOS, as well as Arm64 architecture to extend its reach to Apple silicon on macOS and Snapdragon® compute silicon on Windows, ensuring compatibility with the latest advancements in hardware technology. Redshift GPU performance can be evaluated on systems with compatible Nvidia, AMD and Apple graphics processors.
Unified Benchmarking Scene
Cinebench 2024 streamlines the benchmarking process by utilizing a consistent scene file for both CPU and GPU testing. This innovation enables users to discern the advantages of leveraging Redshift GPU, providing a real-world glimpse into the benefits of harnessing cutting-edge graphics hardware for rendering tasks.
Revamped User Interface
Cinebench 2024 introduces a revamped user interface that enhances the user experience and showcases the incredible artistic endeavors achieved with the Redshift render engine in Cinema 4D. This dynamic interface serves as a testament to the potential of the Redshift engine while offering users a more intuitive and visually engaging experience.
Under-the-Hood Enhancements
Beyond the surface, Cinebench 2024 brings forth a host of performance-enhancing features. With a threefold increase in memory footprint compared to Cinebench R23, the software caters to the memory-intensive demands of modern projects. Moreover, a six-fold rise in computational effort and utilization of newer instruction sets ensures a benchmark that resonates with the complexity and sophistication of contemporary creative projects.
Unparalleled Performance Evaluation
It's crucial to note that Cinebench 2024 scores cannot be directly compared to those of its predecessor, Cinebench R23. With the incorporation of Redshift, a different rendering engine, larger memory footprint, and more complex scenes, Cinebench 2024 offers a distinctly enhanced and accurate evaluation of modern hardware capabilities.
Availability
Cinebench 2024 is immediately available for download starting today on the official Maxon website. Creatives, gamers and technology enthusiasts are invited to explore this groundbreaking benchmarking tool and experience firsthand the leap in performance evaluation that it offers.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is composed of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905630586/en/
Contact information
Press Contact
Chloe Larby
Grithaus Agency
(e) chloe@grithaus.agency
(p) +44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom